-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Adenoid Cystic Carcinoma (ACC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Apatinib Mesylate in Adenoid Cystic Carcinoma (ACC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Adenoid Cystic Carcinoma (ACC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLATE-001 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Metastatic Colorectal Cancer Drug Details: SLATE-001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risperidone ER in Bipolar I Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risperidone ER in Bipolar I Disorder report and make more profitable business decisions.Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risperidone ER in Bipolar I Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Apatinib Mesylate in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Apatinib Mesylate in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Triple-Negative Breast Cancer (TNBC) Drug Details:...
-
Product Insights
NewLeiomyosarcoma – Drugs In Development, 2024
Empower your strategies with our Leiomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal, or soft tissue origin. Symptoms include a noticeable lump or swelling; pain, if it presses on nerves or muscles; and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure,...
-
Product Insights
NewSynovial Sarcoma – Drugs In Development, 2024
Empower your strategies with our Synovial Sarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy. The Synovial Sarcoma drugs in development market research report provide...
-
Product Insights
NewAngiosarcoma – Drugs In Development, 2024
Empower your strategies with our Angiosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Angiosarcoma is a rare type of cancer that that develops in the inner lining of the blood and lymph vessels and is linked to a gene called POTI. Angiosarcoma appears as a bruise-like lesion that grows over time. Once metastatic, it becomes difficult to treat and the survival rate drops to 12-33%. The Angiosarcoma drugs in development market research report provide comprehensive information...
-
Product Insights
NewAdenoid Cystic Carcinoma (ACC) – Drugs In Development, 2024
Empower your strategies with our Adenoid Cystic Carcinoma (ACC) – Drugs In Development, 2024 report and make more profitable business decisions. Adenoid cystic carcinoma (ACC) is a rare and aggressive type of cancer that originates from glandular tissues. It can occur in various parts of the body, but it is most found in the salivary glands of the head and neck region. ACC is characterized by a MYB oncogene activation and a tendency to invade nerves and metastasize to distant organs....
-
Product Insights
NewRecurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024
Empower your strategies with our Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent glioblastoma multiforme (GBM) refers to the return of aggressive brain tumors known as glioblastomas after initial treatment. GBM is the most malignant type of glioma, characterized by rapid growth and infiltrative behavior. Despite aggressive therapies like surgery, radiation, and chemotherapy, GBM often recurs due to its invasive nature and resistance to treatment. Management of recurrent GBM poses significant challenges....